The introduction of the Retatrutide vial marks a notable breakthrough in the landscape to metabolic regulation. This novel therapy combines dual mechanisms – stimulation of the GLP-1 receptor and reduction of the DPP-4 factor – providing a different method for managing obesity . Early patient fin